SusanEDormanMD
Infectious Disease • Charleston, SCAssociate Professor of Medicine, Johns Hopkins University School of Medicine
Are you Dr. Dorman?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 77 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
171 Ashley Ave
Charleston, SC 29425Phone+1 843-792-1414
Summary
- Dr. Susan Dorman, MD is an infectious disease specialist in Charleston, South Carolina. She is currently licensed to practice medicine in South Carolina and Maryland. She is affiliated with MUSC Health University Medical Center and is an Associate Professor of Medicine at Johns Hopkins University School of Medicine.
Education & Training
National Institutes of Health Clinical CenterFellowship, Infectious Disease, 1996 - 1999
Brigham and Women's HospitalResidency, Internal Medicine, 1993 - 1996
Duke University School of MedicineClass of 1993
Certifications & Licensure
SC State Medical License 2017 - 2025
MD State Medical License 1996 - 2018
American Board of Internal Medicine Infectious Disease
Clinical Trials
- TBTC Study 28: Moxifloxacin Versus Isoniazid for TB Treatment Start of enrollment: 2006 Feb 01
- TBTC Study 29: Rifapentine During Intensive Phase Tuberculosis (TB) Treatment Start of enrollment: 2008 Dec 01
- Rifapentine Plus Moxifloxacin for Treatment of Pulmonary Tuberculosis Start of enrollment: 2009 Nov 01
- Join now to see all
Publications & Presentations
PubMed
- Factors associated with tuberculosis treatment initiation among bacteriologically negative individuals evaluated for tuberculosis: An individual patient data meta-anal...Sun Kim, Melike Hazal Can, Tefera B Agizew, Andrew F Auld, Maria Elvira Balcells
Plos Medicine. 2025-01-01 - Pyrazinamide Safety, Efficacy, and Dosing for Treating Drug-Susceptible Pulmonary Tuberculosis: A Phase 3, Randomized Controlled Clinical Trial.Ava Y Xu, Gustavo E Velásquez, Nan Zhang, Vincent K Chang, Patrick P J Phillips
American Journal of Respiratory and Critical Care Medicine. 2024-12-01 - Risk-stratified treatment for drug-susceptible pulmonary tuberculosis.Vincent K Chang, Marjorie Z Imperial, Patrick P J Phillips, Gustavo E Velásquez, Payam Nahid
Nature Communications. 2024-10-30
Press Mentions
Shorter TB Treatment Regimen Demonstrates EfficacyMay 6th, 2021- Program to Present Ideas for Ending TB EpidemicMarch 12th, 2021
- MUSC Physician Wins $9.9 Million Contract to Run Trials for the Tuberculosis Trials ConsortiumFebruary 23rd, 2021
- Join now to see all
Grant Support
- Phase II Study Of Daily Rifapentine For Pulmonary Tuberculosis (Ind 62,611;1/2/0Food And Drug Administration2009–2011
- Extensively Drug-Resistant Tuberculosis Among GOLD Miners In South AfricaNational Institute Of Allergy And Infectious Diseases2008–2011
- Rapid Detection Of Mycobacterium TuberculosisNational Institute Of Allergy And Infectious Diseases2003–2007
- Mycobacterium Tuberculosis Cell Wall Virulence FactorsNational Institute Of Allergy And Infectious Diseases2003–2004
